Articles

  • 1 week ago | seekingalpha.com | Vince Martin

    SummaryBaxter International's stock has been challenging to own for the past decade, initially due to high valuations and later due to execution concerns and an ugly acquisition. During the pandemic, health care stocks, including Baxter, underperformed expectations, with BAX peaking in April 2020 before declining. But the divestiture of the kidney care business will help the balance sheet, and management is optimistic toward 2025 performance.

  • 1 week ago | seekingalpha.com | Vince Martin

    May 06, 2025 4:11 PM ET, , SummaryNewsmax stock surged unrealistically post-IPO, but now trades at a more reasonable $23. Affiliate fees and digital subscriptions both saw sharp increases in 2024, suggesting the potential for revenue growth and margin improvement, allowing the business to grow into a currently high valuation. But 2024 looks like an outlier, with a 26% increase in revenue driven largely by those new launches.

  • 1 week ago | seekingalpha.com | Vince Martin

    SummaryFirst Solar's Q1 earnings call was the one of the most complex you'll find, highlighting the tremendous uncertainty around the business. Key issues include the impact of fluctuating tariffs and their potential long-term effects on the U.S. solar industry's supply chain, along with the future of the 45X tax credit. The core thesis still holds: First Solar is the unquestioned leader in its business, and genAI and other trends will require more solar capacity.

  • 1 week ago | seekingalpha.com | Vince Martin

    SummaryCaesars Entertainment (CZR) stock is trading below its May 2020 levels, despite being a leader in gaming — suggesting room for a huge rally. At just above $27, CZR trades at under 8x EV/EBITDAR, a discount compared to some U.S. peers. The company aggressively bought back shares at $24. But there's a reason why long-term results have been disappointing: clearly, the market simply doesn't quite trust the business or management. CZR has potential upside.

  • 2 weeks ago | seekingalpha.com | Vince Martin

    SummaryChewy has grown impressively from zero revenue in 2011 to nearly $12 billion in fiscal 2024, driven by solid pricing, real value, and excellent customer service. Heading into fiscal 2025, the business seems to be at an "inflection point," with active customer growth returning and margin expansion continuing. Growth prospects remain strong with expansion into pharmacy, vet clinics, and sponsored ads, targeting a $150 billion market.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →